China rejects Gilead’s patent for $1,000-a-day drug
June 19, 2015 at 12:40 PM EDT
China has rejected a patent application for Gilead’s controversial hepatitis C drug, Sovaldi, which costs $1,000 a day.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.